Literature DB >> 8780407

Development of seven new human prostate tumor xenograft models and their histopathological characterization.

W M van Weerden1, C M de Ridder, C L Verdaasdonk, J C Romijn, T H van der Kwast, F H Schröder, G J van Steenbrugge.   

Abstract

Seven human prostate tumor models were established by transplanting tumor fragments in NMRI athymic nude mice. Once established, the tumors were serially transplantable in both NMRI and BALB/c nude mice. The xenografts originated from primary prostatic carcinomas (prostatectomy specimens), transurethral resection material, and metastatic lesions (pelvic lymph nodes and scrotal skin). Histological examination revealed that, in the course of several mouse passages (8 to 23), tumors retained their resemblance to the original patient material. The PC-295, PC-310, PC-329, and PC-346 tumors are dependent on androgens for their growth. The PC-324, PC-339, and PC-374 tumors are androgen independent, although growth of PC-374 tumors still seemed androgen sensitive. All tumors are diploid, except for the PC-374, which is tetraploid. The diploid PC-295 tumor has an additional small population of tetraploid cells. All xenografts displayed a heterogeneous expression pattern of the androgen receptor except for the PC-324 and PC-339 tumors in which the androgen receptor could not be detected. Prostatic acid phosphatase and prostate-specific antigen were retained during serial transplantation in all tumors but the PC-324 and PC-339. This panel of permanent human prostate tumor models comprises tumors representing both the androgen-dependent and -independent stages of human prostate cancer with various degrees of differentiation and, therefore, is of great value for the study of many aspects of growth and progression of human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780407      PMCID: PMC1865169     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  21 in total

1.  Characterization of monoclonal antibodies raised against the prostatic cancer cell line PC-82.

Authors:  M P Gallee; C C van Vroonhoven; H A van der Korput; T H van der Kwast; F J ten Kate; J C Romijn; J Trapman
Journal:  Prostate       Date:  1986       Impact factor: 4.104

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Basement membrane complexes with biological activity.

Authors:  H K Kleinman; M L McGarvey; J R Hassell; V L Star; F B Cannon; G W Laurie; G R Martin
Journal:  Biochemistry       Date:  1986-01-28       Impact factor: 3.162

4.  Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines.

Authors:  R Fridman; G Giaccone; T Kanemoto; G R Martin; A F Gazdar; J L Mulshine
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Biological effects of hormonal treatment regimens on a transplantable human prostatic tumor line (PC-82).

Authors:  G J van Steenbrugge; M Groen; J C Romijn; F H Schröder
Journal:  J Urol       Date:  1984-04       Impact factor: 7.450

6.  Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82).

Authors:  W Hoehn; F H Schroeder; J F Reimann; A C Joebsis; P Hermanek
Journal:  Prostate       Date:  1980       Impact factor: 4.104

7.  Prostatic adenocarcinoma PC EW, a new human tumor line transplantable in nude mice.

Authors:  W Hoehn; M Wagner; J F Riemann; P Hermanek; E Williams; R Walther; R Schrueffer
Journal:  Prostate       Date:  1984       Impact factor: 4.104

8.  A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis.

Authors:  L L Vindeløv; I J Christensen; N I Nissen
Journal:  Cytometry       Date:  1983-03

9.  The use of steroid-containing Silastic implants in male nude mice: plasma hormone levels and the effect of implantation on the weights of the ventral prostate and seminal vesicles.

Authors:  G J van Steenbrugge; M Groen; F H de Jong; F H Schroeder
Journal:  Prostate       Date:  1984       Impact factor: 4.104

10.  CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.

Authors:  M A Wainstein; F He; D Robinson; H J Kung; S Schwartz; J M Giaconia; N L Edgehouse; T P Pretlow; D R Bodner; E D Kursh
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

View more
  45 in total

1.  Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer.

Authors:  M van der Graaf; R G Schipper; G O Oosterhof; J A Schalken; A A Verhofstad; A Heerschap
Journal:  MAGMA       Date:  2000-07       Impact factor: 2.310

Review 2.  Human prostate cancer heterotransplants: a review on this experimental model.

Authors:  Lluis A Lopez-Barcons
Journal:  Asian J Androl       Date:  2010-04-05       Impact factor: 3.285

3.  STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors.

Authors:  R S Hubert; I Vivanco; E Chen; S Rastegar; K Leong; S C Mitchell; R Madraswala; Y Zhou; J Kuo; A B Raitano; A Jakobovits; D C Saffran; D E Afar
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

4.  Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation.

Authors:  A Schäfer; A Pahnke; D Schaffert; W M van Weerden; C M A de Ridder; W Rödl; A Vetter; C Spitzweg; R Kraaij; E Wagner; Manfred Ogris
Journal:  Hum Gene Ther       Date:  2011-08-10       Impact factor: 5.695

Review 5.  Patient-derived xenografts as in vivo models for research in urological malignancies.

Authors:  Takahiro Inoue; Naoki Terada; Takashi Kobayashi; Osamu Ogawa
Journal:  Nat Rev Urol       Date:  2017-02-21       Impact factor: 14.432

6.  Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Authors:  Liqun Chen; Salma Siddiqui; Swagata Bose; Benjamin Mooso; Alfredo Asuncion; Roble G Bedolla; Ruth Vinall; Clifford G Tepper; Regina Gandour-Edwards; Xubao Shi; Xiao-Hua Lu; Javed Siddiqui; Arul M Chinnaiyan; Rohit Mehra; Ralph W Devere White; Kermit L Carraway; Paramita M Ghosh
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

7.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins.

Authors:  Flip H Jansen; Jeroen Krijgsveld; Angelique van Rijswijk; Gert-Jan van den Bemd; Mirella S van den Berg; Wytske M van Weerden; Rob Willemsen; Lennard J Dekker; Theo M Luider; Guido Jenster
Journal:  Mol Cell Proteomics       Date:  2009-02-09       Impact factor: 5.911

9.  Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.

Authors:  M de Visser; H F Bernard; J L Erion; M A Schmidt; A Srinivasan; B Waser; J C Reubi; E P Krenning; M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-08       Impact factor: 9.236

Review 10.  The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.

Authors:  Sheng-Qiang Yu; Kuo-Pao Lai; Shu-Jie Xia; Hong-Chiang Chang; Chawnshang Chang; Shuyuan Yeh
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.